Terazosin
As of the edition of 20 October 2026, Terazosin is a small molecule: marketed, first approved in 1987 (US); acts on ADRA1A, ADRA1B and ADRA1D; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2000
- Kind
- Small molecule
- Brand name
- Hytrin
- First approved
- 7 August 1987 (US)
- Approvals on record
- 11 in 3 regions
- Holder of the most recent approval
- ANI Pharmaceuticals; 4 holders in all
- Registered trials
- 19, 1 stopped early
- Disease areas
- Nervous system; Mental health; Heart and blood vessels; Nutrition and metabolism; Hormones; Pregnancy and women's health
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Companies that need a new molecule because of this drug
3 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product3 company-target rows are on route B because of Terazosin.
See the 3 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 4 | 2 | 0 | 1 |
| Phase 1 | 2 | 0 | 2 | 0 |
| Phase 2 | 8 | 1 | 5 | 0 |
| Phase 3 | 2 | 0 | 2 | 0 |
| Phase 4 | 3 | 2 | 0 | 0 |
| All trials | 19 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Abbott | Originator and Acquired holder | 1987 to now |
| ANI Pharmaceuticals | Later holder | 2024 to now |